
Hinge Health, Inc. has been upgraded from Hold to Buy due to strong Q3 results and improved future outlook. The company reported a 52% revenue increase to $235 million and a non-GAAP operating margin of 33%, with record free cash flow of $112.7 million. It also raised its 2026 revenue midpoint to $880 million and operating profit guidance to $266–268 million, driven by client and program growth. Despite its high valuation, the positive growth and profitability improvements support a more optimistic long-term investment view.
As of Nov 19, 2026 23:31 WIB, Hinge Health Inc. Class A Common Stock (HNGE) trades at USD 110.71 on Pluang, down 3.34% for the day. The stock has a market cap of $9.31 billion and an enterprise value of $9.05 billion. Despite the recent price dip, the company’s strong Q3 results and raised guidance may influence investor sentiment going forward.